{"id":400686,"date":"2020-12-16T07:03:32","date_gmt":"2020-12-16T12:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400686"},"modified":"2020-12-16T07:03:32","modified_gmt":"2020-12-16T12:03:32","slug":"biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/","title":{"rendered":"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema"},"content":{"rendered":"
\n

\n
\n \u2014Direct to patient shipments of the first oral, once-daily\u00a0prophylactic treatment underway through Optime Care<\/em>
\n <\/strong>
\n
\n \u2014<\/em>
\n <\/strong>\u00a0<\/p>\n

\n
\n \u2014EMPOWER Patient Services providing streamlined, single point of contact access to therapy and reimbursement support\u2014<\/em>
\n <\/strong>\u00a0<\/p>\n

RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc.<\/a>\u00a0(Nasdaq:\u00a0BCRX) today announced\u00a0that oral, once-daily ORLADEYO\u2122\u00a0(berotralstat) is now available for shipment to patients with a prescription in the United States.<\/p>\n

ORLADEYO was approved by the U.S. Food and Drug Administration (FDA) on December 3, 2020 for prophylaxis to\u00a0prevent\u00a0attacks of\u00a0hereditary angioedema (HAE)\u00a0in\u00a0adults and pediatric\u00a0patients 12 years and older.\u00a0 Optime Care, Inc., the exclusive specialty pharmacy provider for ORLADEYO, has begun shipping to patients today.<\/p>\n

\u201cAccess to medicine is critical to HAE patients. Many patients have been waiting for an oral option and I am very pleased that they have support from BioCryst to access ORLADEYO so quickly following FDA approval,\u201d said Douglas R. Lotz, M.D., senior partner, Family Allergy & Asthma, Louisville, KY.<\/p>\n

BioCryst is committed to supporting HAE patients taking ORLADEYO through a new program designed to streamline access to therapy. Through EMPOWER Patient Services, each HAE patient and their healthcare provider will have a single point of contact for access to ORLADEYO. A dedicated care coordinator will support access for each patient with comprehensive financial support tools and reimbursement support.<\/p>\n

\u201cOur goal is to provide a best-in-class partnership that enables an individualized approach for physicians and their patients,\u201d said Charlie Gayer, chief commercial officer of BioCryst. \u201cThrough our dedicated care coordinators, we offer a single point of contact to assist patients and healthcare providers throughout the treatment journey. From the transition to ORLADEYO, coordination of deliveries, to ongoing patient support, EMPOWER puts the HAE patient at the center.\u201d<\/p>\n

Additional information is available at\u00a0www.ORLADEYO.com<\/a>\u00a0and\u00a01-866-5-EMPOWER (1-866-536-7693).<\/p>\n

\n About\u00a0ORLADEYO<\/strong>
\n
\n \u2122<\/strong>
\n <\/sup>
\n \u00a0(berotralstat)<\/strong>\u00a0
ORLADEYO\u2122 (berotralstat) is the first and only oral therapy\u00a0designed specifically to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. \u00a0One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.<\/p>\n

\n U.S. Indication and Important Safety Information<\/strong>\n <\/p>\n

\n INDICATION<\/strong>
\n
ORLADEYO\u2122\u00a0(berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.<\/p>\n

\n Limitations of use<\/strong>
\n
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.<\/p>\n

\n IMPORTANT SAFETY INFORMATION<\/strong>
\n
An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.<\/p>\n

The most common adverse reactions (\u226510% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.<\/p>\n

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).<\/p>\n

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John\u2019s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.<\/p>\n

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.<\/p>\n

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.<\/p>\n

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.<\/p>\n

\n To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or\u00a0<\/strong>
\n
\n www.fda.gov\/medwatch<\/strong>
\n <\/a>
\n .<\/strong>\n <\/p>\n

\n Please see full\u00a0<\/strong>
\n
\n Prescribing Information<\/strong>
\n <\/a>
\n .<\/strong>\n <\/p>\n

\n About BioCryst Pharmaceuticals<\/strong>\n <\/p>\n

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO\u2122 (berotralstat) is approved in the United States for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB\u00ae<\/sup>\u00a0(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst\u2019s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company\u2019s website at\u00a0www.biocryst.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\u00a0<\/p>\n

This press release contains forward-looking statements, including statements regarding BioCryst\u2019s plans and expectations for ORLADEYO.\u00a0 These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst\u2019s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.\u00a0Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which\u00a0could create challenges in all aspects of\u00a0BioCryst\u2019s\u00a0business, including without limitation delays, stoppages, difficulties and increased expenses with respect to\u00a0BioCryst\u2019s\u00a0and\u00a0its\u00a0partners\u2019 development, regulatory processes and supply chains, negatively impact\u00a0BioCryst\u2019s\u00a0ability to access the capital or credit markets to finance\u00a0its\u00a0operations, or have the effect of heightening many of the risks described below or in the documents\u00a0BioCryst\u00a0files\u00a0periodically with the Securities and Exchange Commission; BioCryst\u2019s ability to successfully implement its commercialization plans for, and to commercialize,\u00a0ORLADEYO, which could take longer or be more expensive than planned; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, including to support the continued commercialization of ORLADEYO, may not provide regulatory clearances which may result in delay of planned clinical trials,\u00a0may impose certain restrictions, warnings, or other requirements on product candidates,\u00a0including ORLADEYO, may impose a clinical hold with respect to such product candidates, or\u00a0may\u00a0withhold or withdraw market approval for such product candidates;\u00a0BioCryst\u2019s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst\u2019s business; and\u00a0actual financial results may not be consistent with expectations, including that 2020 operating expenses and cash usage may not be within management’s expected ranges.\u00a0\u00a0Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst\u2019s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst\u2019s forward-looking statements.<\/p>\n

BCRXW\u00a0<\/p>\n

\n
\n Contact:<\/u>
\n <\/strong>\u00a0
John Bluth\u00a0
+1 919\u00a0859 7910\u00a0
jbluth@biocryst.com<\/a>\u00a0<\/p>\n

Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com<\/a><\/p>\n

A photo accompanying this announcement is available at:\u00a0https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/d19c2ba3-9191-4d58-a615-2cea7d165d48<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2014Direct to patient shipments of the first oral, once-daily\u00a0prophylactic treatment underway through Optime Care \u2014 \u00a0 \u2014EMPOWER Patient Services providing streamlined, single point of contact access to therapy and reimbursement support\u2014 \u00a0 RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc.\u00a0(Nasdaq:\u00a0BCRX) today announced\u00a0that oral, once-daily ORLADEYO\u2122\u00a0(berotralstat) is now available for shipment to patients with a prescription in the United States. ORLADEYO was approved by the U.S. Food and Drug Administration (FDA) on December 3, 2020 for prophylaxis to\u00a0prevent\u00a0attacks of\u00a0hereditary angioedema (HAE)\u00a0in\u00a0adults and pediatric\u00a0patients 12 years and older.\u00a0 Optime Care, Inc., the exclusive specialty pharmacy provider for ORLADEYO, has begun shipping to patients today. \u201cAccess to medicine is critical to HAE patients. Many patients have been waiting … <\/p>\n

Continue reading “BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400686","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2014Direct to patient shipments of the first oral, once-daily\u00a0prophylactic treatment underway through Optime Care \u2014 \u00a0 \u2014EMPOWER Patient Services providing streamlined, single point of contact access to therapy and reimbursement support\u2014 \u00a0 RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc.\u00a0(Nasdaq:\u00a0BCRX) today announced\u00a0that oral, once-daily ORLADEYO\u2122\u00a0(berotralstat) is now available for shipment to patients with a prescription in the United States. ORLADEYO was approved by the U.S. Food and Drug Administration (FDA) on December 3, 2020 for prophylaxis to\u00a0prevent\u00a0attacks of\u00a0hereditary angioedema (HAE)\u00a0in\u00a0adults and pediatric\u00a0patients 12 years and older.\u00a0 Optime Care, Inc., the exclusive specialty pharmacy provider for ORLADEYO, has begun shipping to patients today. \u201cAccess to medicine is critical to HAE patients. Many patients have been waiting … Continue reading "BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T12:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema\",\"datePublished\":\"2020-12-16T12:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/\"},\"wordCount\":1332,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/\",\"name\":\"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=\",\"datePublished\":\"2020-12-16T12:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/","og_locale":"en_US","og_type":"article","og_title":"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema - Market Newsdesk","og_description":"\u2014Direct to patient shipments of the first oral, once-daily\u00a0prophylactic treatment underway through Optime Care \u2014 \u00a0 \u2014EMPOWER Patient Services providing streamlined, single point of contact access to therapy and reimbursement support\u2014 \u00a0 RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc.\u00a0(Nasdaq:\u00a0BCRX) today announced\u00a0that oral, once-daily ORLADEYO\u2122\u00a0(berotralstat) is now available for shipment to patients with a prescription in the United States. ORLADEYO was approved by the U.S. Food and Drug Administration (FDA) on December 3, 2020 for prophylaxis to\u00a0prevent\u00a0attacks of\u00a0hereditary angioedema (HAE)\u00a0in\u00a0adults and pediatric\u00a0patients 12 years and older.\u00a0 Optime Care, Inc., the exclusive specialty pharmacy provider for ORLADEYO, has begun shipping to patients today. \u201cAccess to medicine is critical to HAE patients. Many patients have been waiting … Continue reading \"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T12:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema","datePublished":"2020-12-16T12:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/"},"wordCount":1332,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/","name":"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=","datePublished":"2020-12-16T12:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAwOSMzODgzMjk5IzIwMDQ3MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-hereditary-angioedema\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioCryst Announces U.S. Availability of ORLADEYO\u2122 (berotralstat)\u00a0for the Treatment of Hereditary\u00a0Angioedema"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400686"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400686\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}